# CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

> clinical trial · VERIFIED · 2026-08-13

Status: NOT_YET_RECRUITING · Sponsor: The First Affiliated Hospital with Nanjing Medical University · Condition: Relapsed/Refractory B-cell Malignancies

- Company: The First Affiliated Hospital with Nanjing Medical University
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07763938

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.